Journal of Comparative Effectiveness Research: 2022 year in review

Allan V, Ramagopalan SV, Mardekian J et al. Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants. J. Comp. Eff. Res. 9(9), 603–614 (2020).

Aponte Ribero V, Daigl M, Martí Y et al. How does risdiplam compare with other treatments for Types 1–3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison. How does risdiplam compare with other treatments for Types 1–3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison. J. Comp. Eff. Res. 11(5), 347–370 (2022).

Leahy TP, Kent S, Sammon C et al. Unmeasured confounding in nonrandomized studies: quantitative bias analysis in health technology assessment. J. Comp. Eff. Res. 11(12), 851–859 (2022).

Simpson A, Ramagopalan SV. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 8. J. Comp. Eff. Res. 11(13), 915–917 (2022).

Samjoo IA, Worthington E, Drudge C et al. Efficacy classification of modern therapies in multiple sclerosis. J. Comp. Eff. Res. 10(6), 495–507 (2021).

Németh B, Molnár A, Bozóki S et al. Comparison of weighting methods used in multicriteria decision analysis frameworks in healthcare with focus on low- and middle-income countries. J. Comp. Eff. Res. 8(4), 195–204 (2019).

Godeberge P, Sheikh P, Lohsiriwat V, Jalife A, Shelygin Y. Micronized purified flavonoid fraction in the treatment of hemorrhoidal disease. J. Comp. Eff. Res. 10(10), 801–813 (2021).

Rafiullah M, Siddiqui K. Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-2019. J. Comp. Eff. Res. 9(18), 1247–1254 (2020).

Hampson G, Towse A, Pearson SD, Dreitlein WB, Henshall C. Gene therapy: evidence, value and affordability in the US health care system. J. Comp. Eff. Res. 7(1), 15–28 (2018).

Samjoo IA, Worthington E, Drudge C et al. Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. J. Comp. Eff. Res. 9(18), 1255–1274 (2020).

Bruce IN, Golam S, Steenkamp J. Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. J. Comp. Eff. Res. 11(10), 765–777 (2022).

Law E, Gavanji R, Walsh S, Haltner A, McTavish R, Cameron C. Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points. J. Comp. Eff. Res. 11(2), 109–120 (2022).

Arora P, Mehta D, Ha J. Impact of telehealth on health care resource utilization during the COVID-19 pandemic. J. Comp. Eff. Res. 11(5), 301–309 (2022).

Zipper R, Lamvu G. Vaginal laser therapy for gynecologic conditions: re-examining the controversy and where do we go from here. 11(11), 843–851 (2022).

Foch C, Allignol A, Hohenberger T, Boutmy E, Schaefer S, Hostalek U. Effectiveness of bisoprolol versus other ?-blockers and other antihypertensive classes: a cohort study in the Clinical Practice Research Datalink. J. Comp. Eff. Res. 11(6), 423–436 (2022).

McDonald CM, Muntoni F, Penematsa V. Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients. J. Comp. Eff. Res. 11(3), 139–155 (2022).

Simpson A, Ramagopalan SV. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 9. J. Comp. Eff. Res. 11(16), 1147–1149 (2022).

Dormer L. Celebrating 10 years of the Journal of Comparative Effectiveness Research. J. Comp. Eff. Res. 11(01), 1–6 (2022).

Wong BL, Cook T, Miller H. Prednisone and deflazacort in Duchenne muscular dystrophy: a patient perspective and plain language summary publication of the Cincinnati study. J. Comp. Eff. Res. 11(11), 779–786 (2022).

Wagg AS, Herschorn S, Carlsson M, Fernet M, Oelke M. A plain language summary of the likelihood of symptom relief for patients taking fesoterodine for overactive bladder. J. Comp. Eff. Res. 11(13), 919–925 (2022).

Mooney V, Baur LA, Bereket A et al. The views of teenagers with obesity, their caregivers, and doctors: a plain language summary of the ACTION Teens global survey. J. Comp. Eff. Res. 12(1), e220164 (2023).

Weghuber D, Boberg K, Dan Hesse D et al. Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study. J. Comp. Eff. Res. 12(2), e220187 (2023).

Richeldi L, Azuma A, Cottin V et al. Plain language summary: clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis. J. Comp. Eff. Res. 12(2), e220142 (2023).

The Evidence Base. https://www.evidencebaseonline.com/

The Evidence Base editorial calendar. https://www.evidencebaseonline.com/editorial-calendar/